1.35
+0.0101(+0.75%)
Currency In USD
| Previous Close | 1.34 |
| Open | 1.38 |
| Day High | 1.43 |
| Day Low | 1.34 |
| 52-Week High | 4.35 |
| 52-Week Low | 1 |
| Volume | 10,290 |
| Average Volume | 55,865 |
| Market Cap | 32.47M |
| PE | -0.35 |
| EPS | -3.91 |
| Moving Average 50 Days | 1.36 |
| Moving Average 200 Days | 2.07 |
| Change | 0.01 |
If you invested $1000 in Celularity Inc. (CELU) since IPO date, it would be worth $13.78 as of February 21, 2026 at a share price of $1.35. Whereas If you bought $1000 worth of Celularity Inc. (CELU) shares 5 years ago, it would be worth $13.22 as of February 21, 2026 at a share price of $1.35.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Celularity Receives $12.2 Million from Sale of New Jersey Net Operating Losses
GlobeNewswire Inc.
Feb 10, 2026 1:30 PM GMT
FLORHAM PARK, N.J., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a longevity-focused regenerative and cellular medicine company, today announced receipt of $12.2 Million in net cash proceeds from the sale of appr
Celularity CEO Comments on Centers for Medicare & Medicaid Services’ Withdrawal of Skin Substitute Local Coverage Determinations
GlobeNewswire Inc.
Dec 26, 2025 1:30 PM GMT
While Celularity’s Biovance® and Biovance 3L products remained eligible for Medicare coverage under the now-withdrawn LCDs, Celularity CEO Dr. Robert J. Hariri welcomed the recent action taken under the leadership of CMS Administrator Dr. Mehmet OzFL
Celularity Announces Closing of Financing Transactions
GlobeNewswire Inc.
Dec 22, 2025 9:01 PM GMT
FLORHAM PARK, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company addressing age-related and degenerative diseases, today announced the closing of its previously disclo